NVAX has had significant down trending over a wide range of time. On the 4H chart it seems to be pivoting from a swing bottom 3-4 days ago. This is accompanied by a cross of the MACD lines under the histogram on that indicator and a flip of volatility on the relative volatility indicator. NVAX has been subject to significant short selling. Price is presently...
Pfizer - Medium Term - We look to Sell at 39.88 (stop at 41.08) Bespoke resistance is located at 40. 40.14 has been pivotal. 40.37 has been pivotal. Daily signals are bearish. We look for a temporary move higher. Our profit targets will be 37.08 and 36.58 Resistance: 37.05 / 38.30 / 39.00 Support: 36.03 / 35.50 / 35.00 Please be advised that the...
Over the past year, investors have been disappointed with Pfizer as the company's stock experienced a significant decline of 28.8%. This decline can be attributed, in part, to the anticipated drop in sales for Pfizer's COVID-19 vaccine, Comirnaty, and its antiviral treatment, Paxlovid. However, there is an overlooked aspect that investors have failed to recognize:...
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under...
This strategy dissects the dual nature of big pharmaceutical firms like Johnson & Johnson, Pfizer, Moderna, and Merck & Co viewed through base Fibonacci Extension Clustering. Despite big pharma's significant contributions to healthcare, these firms have benefited from questionable practices, including price manipulation and exploiting addictions . Price...
NYSE:PFE Pfizer Inc. (PFE) is a leading pharmaceutical company with a diverse portfolio of drugs and products, including vaccines, oncology, and rare disease treatments. The successful rollout of COVID-19 vaccines has been a significant driver of Pfizer's revenue growth, with revenue increasing from HKEX:41 billion in 2020 to HKEX:81 billion in 2021 and...
The price has been traded in a downnsloping channel . We expect the bounce from the donwsloping support. Spelucative long position: entry: 38,43 target: 47,82 stop loss: 37,49
pfizer is gonna make wave c for target TASE:49 at least and HKEX:52
PFE just raised its dividend On the chart it has been trending downward as shown also by a down sloping anchored VWAP bands. Price is currently sitting at long term support and two standard deviations below VWAP. It appears to be ready to reverse from the deep undervalued area. In confirmation, teh voume indicator shows moderate increased...
$PFE has a similar setup to $MRNA here, both are attractive buys from a valuation and technical standpoint here and have been beaten down lately due to the situation with rates, banking woes and negative news about COVID vaccines, COVID lock downs, etc. (a general more negative perception of health measures taken by the US govt since 2020 likely part of the reason...
NVAX as seen on the weekly chart has been in price distress for a long time. It has only one product on the market due to various issues with the FDA process. It has a variety of products in development as linked below. The question is whether it will run out of cash before a sustained revenue stream develops. FDA approvals for the pipeline products could take...
Daily chart formation Trend trade 3IBK + short balance + resistance level - expanding CREEK + volumed 2 Ut - month support level Hourly chart: Conservative trend trade 3IBK + short impulse + 1/2 correction + resistance zone + T2 level + volumed 2Ut
PFE evening star reversal countertrend wave 2 of uptrend
The PFE stock, Pfizer, Inc., looks like is about to take a deep dive... Going red... Let's have a look! The most obvious signal is the weekly candle today moving below EMA50, telling us that this stock is preparing to drop for months. Pfizer, Inc. peaked December 2021. In mid-December 2022 PFE printed the inverted hammer bearish candlestick pattern or shooting...
SPY - Interesting day on SPY. We said yesterday that the markets could realistically go either way, but we were watching more so to the downside due to the failed 2U formed on Monday that was followed by a 2D yesterday, and having that small bearish bias by simply playing what is in front of us vs using other reasons for bias. SPY ended up gapping up premarket and...
You may be familiar with the negative sentiment surrounding Pfizer, with many citing the company's heavy reliance on its COVID-19 vaccine Comirnaty and antiviral therapy Paxlovid as a cause for concern. In addition to this, several of Pfizer's top-selling drugs will face patent expirations in the near future, leading many to believe that the company's stock will...
PFE beat analysts' estimates on EPS but provided an outlook that didn`t meet expectations. However, The Co expects revenues to grow by 7-9% in 2023. Considering its plans to boost business by acquiring SGEN, the current market cap looks attractive as a reverse to mean play and a fundamentally driven long-term investment case.
Buy Feb-24-23 43.5 Calls @ 0.1 Limit to Open (Weekly) Buy Mar-24-23 47 Calls @ 0.11 Limit to Open (Monthly (W))